English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The present study quantifies the effect of the two botulinum toxin type A products, Xeomin and Dysport, with approval from the National Agency for Medicines and Medical Devices of Romania (ANMDMR), for the treatment of the spastic upper limb following a stroke. The results obtained in the present study show a good efficiency of using both products in the spasticity of the upper limb, and a maintenance of the results obtained for both products for a minimum period of 3 months. Also, at higher doses, the results of the study show better improvement of spasticity and upper limb function on the evaluation scales, but the local effect is not maintained for a longer period.Keywords: toxinum botulinum type A, Xeomin, Dysport, spasticity

Efficiency of Different Preparations of Botulinum Toxin Type A, Xeomin and Dysport, in the Management of Spastic Upper Limb After Stroke